10 patients, but one dropped out, so 9. 6 were given a negligible dose for safety and one of these later died. One of the three remaining lied about heart issues and had a serious heart attack immediately after injection. So at best you have a sample size of two. Two people!!
Really not the promising study the title suggests.
"They plan to enroll ~40 more patients.
Meanwhile a new version of the therapy, VERVE-102, is in the works. The newcomer uses a similar base editing technology and an upgraded nanoparticle carrier with potentially better targeting.
The team plans to launch a randomized, placebo-controlled trial by 2025"
1 comment
[ 316 ms ] story [ 2367 ms ] threadReally not the promising study the title suggests.
"They plan to enroll ~40 more patients.
Meanwhile a new version of the therapy, VERVE-102, is in the works. The newcomer uses a similar base editing technology and an upgraded nanoparticle carrier with potentially better targeting.
The team plans to launch a randomized, placebo-controlled trial by 2025"
So that might be promising, albeit later.